Profile data is unavailable for this security.
About the company
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
- Revenue in USD (TTM)24.79m
- Net income in USD-84.93m
- Incorporated2014
- Employees65.00
- LocationZevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
- Phone+1 (321) 939-3416
- Fax+1 (319) 665-2577
- Websitehttps://zevra.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | 247.00m | -180.81m | 391.29m | 597.00 | -- | -- | -- | 1.58 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 415.77m | 135.00 | -- | -- | -- | 7.06 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 458.70m | 147.00 | 120.41 | -- | 79.11 | 2.91 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 460.66m | 377.00 | -- | -- | -- | 2.46 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 462.47m | 45.00 | 6.16 | 3.08 | 5.36 | 2.66 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 463.29m | 99.00 | -- | 2.51 | -- | 7.33 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 496.53m | 240.00 | -- | -- | -- | 1.68 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 511.61m | 65.00 | -- | 7.24 | -- | 20.64 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 513.67m | 1.60k | -- | 1.05 | -- | 0.4564 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 651.52m | -78.97m | 525.69m | 2.52k | -- | 0.6206 | -- | 0.8069 | -0.3013 | -0.3013 | 2.47 | 3.25 | 0.6062 | 4.98 | 36.38 | 258,951.60 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 593.50m | 76.00 | -- | 36.22 | -- | 258.53 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| CorMedix Inc | 12.26m | -46.15m | 604.35m | 82.00 | -- | 9.81 | -- | 49.29 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Eyepoint Pharmaceuticals Inc | 45.71m | -103.57m | 609.46m | 121.00 | -- | 2.26 | -- | 13.33 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 26.27m | -339.45m | 638.64m | 452.00 | -- | -- | -- | 24.31 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Elite Pharmaceuticals Inc | 71.17m | -6.39m | 658.91m | 64.00 | -- | 13.70 | -- | 9.26 | -0.0059 | -0.0059 | 0.0677 | 0.0443 | 0.8957 | 2.68 | 4.46 | 1,112,051.00 | -8.04 | 19.07 | -10.06 | 24.29 | 44.73 | 46.63 | -8.98 | 20.77 | 2.42 | 0.75 | 0.1634 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
Data as of Nov 25 2024. Currency figures normalised to Zevra Therapeutics Inc's reporting currency: US Dollar USD
38.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Woodline Partners LPas of 30 Sep 2024 | 4.05m | 7.69% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 2.92m | 5.56% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.88m | 5.47% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.69m | 5.12% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 2.18m | 4.15% |
| Altium Capital Management LPas of 30 Sep 2024 | 1.70m | 3.23% |
| 683 Capital Management LLCas of 30 Sep 2024 | 1.23m | 2.33% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.04m | 1.98% |
| J. Goldman & Co. LPas of 30 Sep 2024 | 984.18k | 1.87% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 772.83k | 1.47% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
